Clarivate Epidemiology’s coverage of primary sclerosing cholangitis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of primary sclerosing cholangitis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s primary sclerosing cholangitis forecast will answer the following question:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of primary sclerosing cholangitis over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts two primary sclerosing cholangitis patient populations, as follows:
Literature review (studies included in / excluded from the analyses of primary sclerosing cholangitis)
Diagnosed incident cases
Diagnosed prevalent cases
Risk/protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviation Table
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
